Pharmaceuticals: Commission refines intellectual property rules

Pharmaceuticals 2018 European Commission

The EPO – European Patent Office, has announced the 15 inventors short-listed for this prestigious prize – pioneers in a range of technical fields, from green plastics and oil-spill clean-up, to pharmaceuticals, medical imaging and satellite navigation. Gert-Jan Gruter (The Netherlands), nominated for the European Inventor Award 2017 in the category “Small and medium-sized enterprises – SMEs”. © European Patent Organisation , 2017 / Source: EC – Audiovisual Service / Photo: Heinz Troll

This article is brought to you in association with the European Commission.

The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

The EU has a strong intellectual property rights framework in place which protects Europe’s know-how and sustains the pharmaceutical industry’s world-class innovation capacity. To improve the current system further and remove a major competitive disadvantage of EU manufacturers, the Commission proposes a targeted amendment: the so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

Supplementary Protection Certificates (SPCs) extend patent protection for medicinal products which must undergo lengthy testing and clinical trials prior to obtaining regulatory marketing approval. Thanks to the waiver, in the future EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, if done exclusively for the purpose of exporting to a non-EU market where protection has expired or never existed. The waiver will support Europe’s pioneering role in pharmaceutical research and development.

Vice-President Jyrki Katainen, responsible for Jobs, Growth Investment and Competitiveness, said: “Europe is and should remain at the forefront of pharmaceutical research and manufacturing. Our rules on intellectual property protection of pharmaceuticals promote innovation and creativity. We are committed to the core rights and the length of this protection, which remain unchanged. Today we are proposing a well-calibrated adjustment to the current regime to remove a legal barrier that was preventing our companies from competing on equal terms on global markets where competition is fierce. We want to make sure that our pharmaceutical industry reaps the benefits of such competition.”

Elżbieta Bieńkowska, Commissioner for Internal Market, Industry, Entrepreneurship and SMEs, added: “Today’s proposal strikes a balance between the imperative to ensure the attractiveness of Europe for innovative pharmaceutical companies and the urgency to allow EU based generics and biosimilar to compete on the global markets. This will help create growth and high-skilled jobs in the EU. It could generate €1 billion net additional sales per year and up to 25 000 new jobs over 10 years. It will particularly benefit the many small and medium-sized enterprises in the field. In the medium term, more competition will improve patients’ access to a wider choice of medicines and alleviate public budgets.”

With the waiver, intellectual property (IP) protection for medicine production in Europe will remain the strongest in the world. SPC-protected medicines will retain their full market exclusivity in the EU.

The proposal is accompanied by a series of safeguards which will create transparency and prevent IP-infringing products from entering Member State markets. It goes hand in hand with other EU initiatives to defend Europe’s know-how and innovation leadership and protect patients against counterfeited medicines. It also complements the EU’s overall approach to ensure free and fair trade, characterised by open markets, for EU-based manufacturers.

Today’s proposal amends Regulation 469/2009 on the supplementary protection certificate for medicinal products. Once adopted by the European Parliament and Council, it will be directly applicable in all EU Member States.

Background

EU and global pharmaceutical markets are undergoing profound changes. Global demand for medicines has increased massively, reaching over €1 trillion in 2017. Alongside this, there is a shift towards an ever-greater market share for generics and biosimilars. Traditionally the EU has played a pioneering role in pharmaceutical research and development, including generic medicines and biosimilars. But this leadership position is under threat.

Supplementary protection certificates (SPCs) are an intellectual property right first introduced in the EU in 1992 as an extension to a patent right. Pharmaceutical SPCs aim to offset the loss of effective patent protection for medicines that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.

EU SPC rules are the strongest in the world. While they aim to reward investment in innovation and protect intellectual property, SPCs can put EU based manufacturers of generics and biosimilar at a disadvantage with non-EU based industry, thereby preventing further innovation and job creation in Europe. Indeed, during the SPC period of protection of the product in the EU, EU-based manufacturers of generic and/or biosimilar-related products cannot currently manufacture for any purpose, including export outside the EUto countries where SPC protection has expired or does not exist, while manufacturers based in those non-EU countries can do so. This major competitive disadvantage entails a risk of delocalisation of manufacturing and loss of investment in Europe. The certificate also makes it more difficult for EU manufacturers to enter the EU market immediately after its expiry, given that they are not in a position to build up production capacity until the protection provided by the certificate has lapsed.

Many SPC protections will start to lapse from 2020, as a significant number of medicinal products will enter the public domain, since their patent or SPC terms will expire. This development will generate significant new market opportunities for generics, and for biosimilars in particular. There is an urgent need to adjust the existing regulation to this situation, as the markets for generics and biosimilars are highly competitive and steadily growing and the investment decisions on the localisation of the production are being made well in advance.

Today’s proposal was announced in the Commission’s 2015 Single Market Strategy, and follows various studies, an extensive consultation and a European Parliament resolution endorsing the need to introduce before 2019 an SPC manufacturing waiver.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

the European Sting Milestones

Featured Stings

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Draghi tells the Parliament the ECB to use all its weaponry; euro slides to parity with the dollar

What next for Europe? Three (completely) different Davos views

Spring 2019 Economic Forecast: Growth continues at a more moderate pace

Most ‘precious’ and ‘scarce’ resource of our time is dialogue, UN chief tells Doha policy forum

EU-wide penalties for money laundering: deal with Council

In Bali, UN chief Guterres outlines importance of international financial cooperation for sustainable development

Investors have a role in securing our shared digital future

ILO and EIB join forces for more and better quality employment

UN condemns ‘cowardly’ attack on Libya’s national oil corporation headquarters

Search Engine neutrality in Europe in danger: Are 160.000 Google filtering requests good enough?

Why do medical students need to emigrate to become doctors in 2017?

‘Critical moment’ for sustainable development, UN chief tells major financing forum

European Youth Forum welcomes strong stance on human rights in State of the Union

Drinking water: new plans to improve tap water quality and cut plastic litter

UN chief pays tribute to Egypt’s role in avoiding ‘dramatic’ escalation in conflict across the Gaza-Israel border

Why and how did ISIS and Muslim fundamentalism gain momentum this year?

Macron leads EU-wide minimum wage call as Merkel, Medvedev warn of global injustice

One small flight for a drone, one ‘big leap’ for global health

Is there a cure for corruption in Greece?

Keep Africa’s guns ‘from firing in the first place’, UN political chief urges

UN chief expresses solidarity with Indonesian authorities after flash floods kill dozens in Papua

MEPs demand end to EU arms exports to Saudi Arabia

China is the first non-EU country to invest in Europe’s €315 billion Plan

Moratorium call on surveillance technology to end ‘free-for-all’ abuses: UN expert

How bad could British healthcare get for its citizens abroad post-Brexit?

New SDG Advocates sign up for ‘peace, prosperity, people’ and planet, on the road to 2030

Laws must protect, ‘not reject’ says UNAIDS chief on Zero Discrimination Day

Can Eurozone’s uncertain growth answer the challenges that lie ahead?

The West and Russia accomplished the dismembering and the economic destruction of Ukraine

How the Irish people were robbed by banks, the Commission and their own government

Yanis Varoufakis: “Unsustainable debt turns the creditor into Leviathan; Life under it is becoming nasty, brutish and short”

The refugee crisis seen through the eyes of a young doctor from Turkey

TTIP is not dead as of yet, the 15th round of negotiations in New York shouts

Central banking in times of complexity

Juncker’s Investment Plan in desperate need for trust and funds from public and private investors

EU elections: The louder the threats and the doomsaying the heavier the weight of the vote

What do toilets have to do with climate change?

The vehicles of our future

Turkey remains numb while its economy is expected to shrink further due to a cocktail of EU and US sanctions

Debunked: 5 myths about the future of work

“We need to use the momentum globally to ensure that corporations pay their fare share of taxation”, EU Commissioner Valdis Dombrovskis outlines from the World Economic Forum 2017.

European Youth Forum welcomes the European Commission’s proposed revision of the Union Code on Visas, however it does not go far enough

India is a latecomer to AI. Here’s how it plans to catch up

Modern farming is harming the planet. Tech-driven permaculture could heal it

Climate Change Revolution: by-laws for the world

Libya stands at a ‘critical juncture’, UN mission head tells Security Council

Everybody against Germany over the expensive euro

The untold story of who caused and who pays for the economic crisis

The EU to fight cross-border tax evasion with a toothless directive

Brexit poses ‘particular risk’ to British people in poverty: UN independent expert

This app uses augmented reality to rewrite ‘herstory’

Brexit: Only Corbyn and May in concert can make the needed compromises

This is why Dutch teenagers are among the happiest in the world

The EU Parliament sidesteps the real issues about banks, while the US target the Eurozone lenders

How to have a good Fourth Industrial Revolution

Migration crisis update: What are the chances of a fair deal at this EU Summit?

EU finally agrees on target for 40% greenhouse emission cuts ahead of Paris climate talks

Central African Republic: Guterres says UN mission committed to protecting civilians, helping stabilize country, as violence flares

Digital Single Market: New EU rules for online subscription services

It’s not your imagination, summers are getting hotter

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s